Drugs / INO-8875
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01123772 | May 2010 → Feb 2011 | — | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT01123785 | May 2010 → Dec 2011 | glaucoma, ocular hypertension | Inotek Pharmaceuticals Corporation | Completed | Met primary |
Press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-8875 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01123772 ↗ |
| Action | Activate | “Adenosine agonist eye drop” NCT01123785 ↗ |
| Route | Topical | “Topical Ocular Application of INO-8875” NCT01123772 ↗ |